Optimizing treatments for lymphangioleiomyomatosis

Expert Review of Respiratory Medicine

Volumn 6, Issue 3, 2012, Pages 267-276

  Taveira Dasilva, Angelo M ^a   Moss, Joel ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

chylous effusions; lung function decline; lymphangioleiomyomas; lymphangioleiomyomatosis; sirolimus; tuberous sclerosis complex

Indexed keywords

ANTIESTROGEN; CHLOROQUINE; CYCLIN DEPENDENT KINASE INHIBITOR; DOXYCYCLINE; ESTROGEN; ESTROGEN RECEPTOR; EZRIN; GAMMA INTERFERON; GONADORELIN; HAMARTIN; INSULIN; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MOESIN; PROGESTERONE; PROTEIN P27; RADIXIN; RAPAMYCIN; STATIN; TUBERIN; VASCULOTROPIN INHIBITOR;

ACTIN FILAMENT; ASCITES; AUTOPHAGY; CELL CYCLE PROGRESSION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CHYLOTHORAX; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LUNG FUNCTION; LUNG METASTASIS; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MULTICENTER STUDY (TOPIC); NEUROPATHY; PAIN; PLEURA EFFUSION; PLEURODESIS; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TENESMUS; TREATMENT DURATION; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; URINARY FREQUENCY; UTERUS MYOMA;

EID: 84863923458     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.26     Document Type: Review

References (102)

1. Ryu JH, Moss J, Beck GJ et al.; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med. 173(1), 105-111 (2006
2. Ferrans VJ, Yu ZX, Nelson WK et al. Lymphangioleiomyomatosis (LAM). A review of clinical and morphological features. J. Nippon. Med. Sch. 67, 311-329 (2000
3. Johnson SR, Cordier JF, Lazor R et al.; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur. Respir. J. 35(1), 14-26 (2010
4. Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am. J. Clin. Pathol. 93(5), 609-614 (1990
5. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am. J. Clin. Pathol. 96(4), 529-535 (1991
6. Valencia JC, Pacheco-Rodriguez G, Carmona AK et al. Tissue-Specific renin-Angiotensin system in pulmonary lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 35(1), 40-47 (2006
7. Valencia JC, Matsui K, Bondy C et al. Distribution and mRNA expression of insulin-Like growth factor system in pulmonary lymphangioleiomyomatosis. J. Investig. Med. 49(5), 421-433 (2001
8. Pacheco-Rodriguez G, Steagall WK, Crooks DM et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res. 67(21), 10573-10581 (2007
9. Pacheco-Rodriguez G, Kumaki F, Steagall WK et al. Chemokine-Enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J. Immunol. 182(3), 1270-1277 (2009
10. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann. NY Acad. Sci. 615, 125-127 (1991
11. Urban TJ, Lazor R, Lacronique J et al. Pulmonary lymphangioleiomyomatosis, a study of 69 patients. Medicine 78, 321-337 (1999
12. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am. J. Hum. Genet. 62(4), 810-815 (1998
13. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 97(11), 6085-6090 (2000
14. Goncharova EA, Goncharov DA, Eszterhas A et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277(34), 30958-30967 (2002
15. Cai X, Pacheco-Rodriguez G, Fan QY et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 182(11), 1410-1418 (2010
16. Crooks DM, Pacheco-Rodriguez G, DeCastro RM et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 101(50), 17462-17467 (2004
17. Knudson AG. Hereditary cancer: Two hits revisited. J. Cancer Res. Clin. Oncol. 122(3), 135-140 (1996
18. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation, new insights into pathogenesis. Human Pathol. 34, 95-98 (2003
19. Karbowniczek M, Astrinidis A, Balsara BR et al. Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am. J. Respir. Crit. Care Med. 167(7), 976-982 (2003
20. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38(4), 376-381 (2003
21. Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: Comparison of CT features. Radiology 242(1), 277-285 (2007
22. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int. J. Gynaecol. Obstet. 52(3), 289-290 (1996
23. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 57(12), 1085-1086 (2002
24. Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 117(1), 25-30 (2000
25. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136(11), 4996-5003 (1995
26. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-Associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am. J. Physiol. Lung Cell Mol. Physiol. 286(4), L694-L700 (2004
27. Yu JJ, Robb VA, Morrison TA et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc. Natl Acad. Sci. USA 106(8), 2635-2640 (2009
28. Glassberg MK, Elliot SJ, Fritz J et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-Induced cell invasiveness. J. Clin. Endocrinol. Metab. 93(5), 1625-1633 (2008
29. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126(6), 1867-1874 (2004
30. Baldi BG, Medeiros Junior P, Pimenta SP, Lopes RI, Kairalla RA, Carvalho CR. Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis. J. Bras. Pneumol. 37(3), 375-379 (2011
31. Riemsma R, Forbes CA, Kessels A et al. Systematic review of aromatase inhibitors in the first-Line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res. Treat. 123(1), 9-24 (2010
32. Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges. J. Cell. Biochem. 103(2), 369-382 (2008
33. Krymskaya VP, Goncharova EA. PI3K/ mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle 8(3), 403-413 (2009
34. Lamb RF, Roy C, Diefenbach TJ et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2(5), 281-287 (2000
35. Rosner M, Hanneder M, Siegel N, Valli A, Hengstschläger M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res. 658(3), 234-246 (2008
36. Polak P, Hall MN. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 21(2), 209-218 (2009
37. Loewith R, Jacinto E, Wullschleger S et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10(3), 457-468 (2002
38. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-Insensitive and raptor-Independent pathway that regulates the cytoskeleton. Curr. Biol. 14(14), 1296-1302 (2004
39. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-Dependent manner. J. Biol. Chem. 278(35), 32493-32496 (2003
40. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-Activating protein complex toward Rheb. Curr. Biol. 13(15), 1259-1268 (2003
41. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5(6), 578-581 (2003
42. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16(12), 1472-1487 (2002
43. Carrière A, Cargnello M, Julien LA et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSKmediated raptor phosphorylation. Curr. Biol. 18(17), 1269-1277 (2008
44. Haar EV, Lee S, Bandhakavi S, Griffin TJ, Kim D-H. Insulin signaling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature Cell Biol. 9, 316-323 (2007
45. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 28(12), 4104-4115 (2008
46. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor- mTOR complex. Science 307(5712), 1098-1101 (2005
47. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl Acad. Sci. USA 101(37), 13489-13494 (2004
48. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk: IMPLICATIONS for tuberous sclerosis and cancer pathogenesis. Cell 121(2), 179-193 (2005
49. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4(9), 648-657 (2002
50. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/akt pathway. Mol. Cell 10(1), 151-162 (2002
51. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377(6548), 441-446 (1995
52. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22(2), 159-168 (2006
53. Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8), 3509-3512 (2007)
54. Foster DA. Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. Biochim. Biophys. Acta 1791(9), 949-955 (2009
55. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: Competition with rapamycin. Mol. Cell. Biol. 29(6), 1411-1420 (2009
56. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr. Res. 57(1), 67-75 (2005
57. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358(2), 140-151 (2008
58. Taillé C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann. Intern. Med. 146(9), 687-688 (2007
59. Sugimoto R, Nakao A, Yamane M et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after livingdonor lobar lung transplantation. J. Heart Lung Transplant. 27(8), 921-924 (2008
60. Ohara T, Oto T, Miyoshi K et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann. Thorac. Surg. 86(6), e7-E8 (2008
61. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-Cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363(19), 1801-1811 (2010
62. McCormack FX, Inoue Y, Moss J et al.; National Institutes of Health Rare Lung Diseases ConsortiumMILES Trial Group;. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364(17), 1595-1606 (2011
63. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann. Intern. Med. 154(12), 797-805 (2011
64. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomatosis: ABDOMINOPELVIC CT and US findings. Radiology 216(1), 147-153 (2000
65. Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J. Lymphatic involvement in lymphangioleiomyomatosis. Ann. NY Acad. Sci. 1131, 206-214 (2008
66. Seyama K, Kumasaka T, Souma S et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat. Res. Biol. 4(3), 143-152 (2006
67. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N. Engl. J. Med. 358(2), 199-200 (2008
68. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 35(5), 1293-1300 (2009
69. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51 (2011
70. Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K. Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch. Pathol. Lab. Med. 127(7), 879-882 (2003
71. Llopis I, Arandiga R, Real E et al. Lymphangiomyomatosis mimicking an abdominal lymphoma. Haematologica 87(10), EIM23 (2002
72. Wong YY, Yeung TK, Chu WC. Atypical presentation of lymphangioleiomyomatosis as acute abdomen: ct diagnosis. AJR. Am. J. Roentgenol. 181(1), 284-285 (2003
73. Casanova A, María Girón R, Acosta O, Barrón M, Valenzuela C, Ancochea J. Lymphangioleiomyomatosis treatment with sirolimus. Arch. Bronconeumol. 47(9), 470-472 (2011
74. Piha-Paul SA, Hong DS, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus)-Based treatment. J. Clin. Oncol. 29(12), e333-E335 (2011
75. Neurohr C, Hoffmann AL, Huppmann P et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir. Res. 12, 66 (2011
76. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-Dependent feedback loop in human cancer. J. Clin. Invest. 118(9), 3065-3074 (2008
77. Mi R, Ma J, Zhang D, Li L, Zhang H. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. J. Genet. Genomics 36(6), 355-361 (2009
78. Makovski V, Haklai R, Kloog Y. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: A potential treatment for lymphangioleiomyomatosis. Int. J. Cancer 130(6), 1420-1429 (2012
79. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch. Pathol. Lab. Med. 124(2), 267-275 (2000
80. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: A complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am. J. Respir. Cell Mol. Biol. 28(5), 546-550 (2003
81. Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat. Res. Biol. 4(2), 83-100 (2006
82. Gilbertson-Beadling S, Powers EA, Stamp-Cole M et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a nonmetalloproteinase- dependent mechanism. Cancer Chemother. Pharmacol. 36(5), 418-424 (1995
83. Chang WY, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-Related cells. Am. J. Physiol. Lung Cell Mol. Physiol. 299(3), L393-L400 (2010
84. Moir LM, Ng HY, Poniris MH et al. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br. J. Pharmacol. 164(1), 83-92 (2011
85. Pimenta SP, Baldi BG, Acencio MM, Kairalla RA, Carvalho CR. Doxycycline use in patients with lymphangioleiomyomatosis: Safety and efficacy in metalloproteinase blockade. J. Bras. Pneumol. 37(4), 424-430 (2011
86. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res. 67(20), 9878-9886 (2007
87. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ. Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Mol. Cancer Ther. 8(7), 1799-1807 (2009
88. Goncharova EA, Goncharov DA, Li H et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol. Cell. Biol. 31(12), 2484-2498 (2011
89. Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 9, 8 (2009
90. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-Gamma-Jak-Signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: Synergistic effects of rapamycin- IFN-Gamma treatment. Cancer Res. 64(10), 3436-3443 (2004
91. El-Hashemite N, Kwiatkowski DJ. Interferon-Gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: A potential therapeutic target. Am. J. Respir. Cell Mol. Biol. 33(3), 227-230 (2005
92. Goncharova EA, Goncharov DA, Chisolm A et al. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-Dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-Derived cell proliferation. Mol. Pharmacol. 73(3), 778-788 (2008
93. Rosner M, Freilinger A, Hengstschläger M. The tuberous sclerosis genes and regulation of the cyclin-Dependent kinase inhibitor p27. Mutat. Res. 613(1), 10-16 (2006
94. Burgstaller S, Rosner M, Lindengrün C et al. Tuberin, p27 and mTOR in different cells. Amino Acids 36(2), 297-302 (2009
95. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 9(3), 153-166 (2009
96. Lacher MD, Pincheira R, Zhu Z et al. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-Independent mechanisms: IMPLICATIONS for cell proliferation and tumorigenesis. Oncogene 29(50), 6543-6556 (2010
97. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: Therapeutic implications. Mol. Cancer Ther. 10(9), 1533-1541 (2011
98. Yu J, Parkhitko AA, Henske EP. Mammalian target of rapamycin signaling and autophagy: Roles in lymphangioleiomyomatosis therapy. Proc. Am. Thorac. Soc. 7(1), 48-53 (2010
99. Solomon VR, Lee H. Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625(1-3), 220-233 (2009
100. Carbone M. Feasibility of immunotherapy for lymphangioleiomyomatosis. Am. J. Pathol. 175(6), 2252-2254 (2009
101. Klarquist J, Barfuss A, Kandala S et al. Melanoma-Associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am. J. Pathol. 175(6), 2463-2472 (2009
102. Dilling DF, Gilbert ER, Picken MM, Eby JM, Love RB, Le Poole IC. A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am. J. Respir. Cell Mol. Biol. 46(1), 1-5 (2012)